Benitec Biopharma Inc.
BNTC
$14.10
$0.322.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -242.10% | -118.60% | -8.22% | 15.03% | -1.27% |
| Total Depreciation and Amortization | 29.67% | 17.78% | 1.25% | 10.98% | 8.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,862.78% | 1,252.60% | 90.43% | 378.02% | 260.32% |
| Change in Net Operating Assets | -738.89% | 264.21% | -148.13% | -104.40% | 147.75% |
| Cash from Operations | -149.41% | 49.97% | -43.58% | -0.20% | 19.58% |
| Capital Expenditure | -- | 96.65% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 96.65% | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -1.61% | -- | 45,730.77% | -29.88% | -- |
| Repurchase of Common Stock | -- | -23,156.41% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,241.46% | 96,012.82% | -- | -- | -- |
| Cash from Financing | -93.65% | -- | 45,725.64% | -22.44% | -- |
| Foreign Exchange rate Adjustments | -2,300.00% | -118.26% | 273.62% | -306.67% | -123.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -115.74% | 505.99% | 290.20% | -27.41% | 1,002.40% |